ProCE Banner Activity

TOTEM: Intensive vs Minimalist Follow-up in Patients Treated for Endometrial Cancer

Slideset Download
Conference Coverage
In the randomized TOTEM trial, intensive follow-up did not improve overall survival, relapse-free survival, or health-related quality-of-life outcomes vs minimalist follow-up in patients treated for endometrial cancer.

Released: June 10, 2021

Expiration: June 09, 2022

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

Amgen, Inc.

AstraZeneca

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Exelixis

Gilead Sciences, Inc.

GlaxoSmithKline

Ipsen Biopharmaceuticals Inc

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Pfizer, Inc.

Pharmacyclics LLC an AbbVie Company and Janssen Biotech Inc

Sanofi Genzyme